Total Neoadjuvant Treatment Combining Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma

What this Trial Is About

Researchers are evaluating a total neoadjuvant therapy approach for patients with locally advanced esophageal squamous cell carcinoma ESCC. This study aims to improve outcomes by combining induction immunochemotherapy with chemoradiotherapy before surgery. The treatment involves using anti-PD-1 or anti-PD-L1 immune checkpoint inhibitors plus cisplatin-based chemotherapy, which has shown promise in late-stage ESCC by increasing tumor response and survival. Participants receive induction immunochemotherapy including Tislelizumab, Paclitaxel, and Cisplatin administered intravenously every three weeks for two cycles. This is followed by chemoradiotherapy consisting of weekly doses of Paclitaxel and Cisplatin along with radiation therapy delivered five days a week for 25 sessions. After these treatments, surgery is performed to remove the tumor. Throughout the study, participants are closely monitored with assessments including pathological response to treatment measured over an average of six months. Researchers will evaluate outcomes such as disease-free survival, event-free survival, distant metastasis rates, and overall survival for up to 50 months. Safety and disease recurrence are also tracked. Participation lasts through treatment, surgery, and follow-up to understand the therapys impact on tumor control and survival.

Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma